The nation of Zimbabwe has turned down a substantial American health deal valued at $367m (£272m) spanning five years over Washington's insistence on confidential biological samples.
This move came to light after a official document dated December was leaked, revealing that President Emmerson Mnangagwa deemed the deal was "skewed".
A government spokesperson has since clarified that the US was demanding access to genetic material for research and commercial purposes while was not willing to share the resulting advantages from future medical innovations.
"We must now begin the difficult and regrettable process of ending our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for further talks to find a agreement agreeable to all parties so the country's critical HIV treatment initiative can continue.
Wider Context
This development follows a similar situation in neighbouring Kenya, where a court suspended a related deal with the US after concerns were filed about the safety of citizens' medical information.
Since returning to office recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had managed assistance for the American government, but Trump stated its spending was "wasteful" and his government was seeking government-to-government agreements to enhance transparency and accountability.
As per reports, Sixteen nations in Africa have to date signed similar agreements, constituting more than $18.3bn in new funding.
Details of the Rejected Deal
The funds for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation would have delivered extraordinary benefits for the people of Zimbabwe, especially the 1.2 million currently on antiretroviral therapy via American-funded initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to share its genetic material and health information for a long time, with no equivalent guarantee of benefiting from any medical innovations – such as new medicines or tests – that might be developed from that provided information," Mangwana explained.
"Effectively, our nation would supply the raw materials for medical research without any assurance that the final treatments would be accessible to our citizens should a new pandemic emerge."
National Interest and International Frameworks
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were disrupting systems previously set up through the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing system created to deal with potential global health emergencies.
"This system is intended to ensure that when a country provides its data, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to develop them."
These objections regarding the US deal "should not be misconstrued as opposition to America," he added.
"We are open to continued dialogue with our US partners on how future co-operation could be arranged in a manner that honours the independence and interests of both nations."
Health Experts Reaction
A leading public health body said it recognised the official position, but suggested that negotiations need to persist considering much of the country's HIV programmes relied on external financing.
"If technical issues exist, including those involving data governance or implementation frameworks, these can often be resolved via technical clarification and negotiated safeguards," it added.
The situation highlights the ongoing tensions between accepting vital foreign assistance and safeguarding national sovereignty in an ever more data-driven world.